Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Pulmonary surfactant

Beractant

Survanta

Dosage form
Tablet
Available strengths
100 mg phospholipids/4 mL, 200 mg phospholipids/8 mL
Drug class
Pulmonary surfactant
Common brand
Survanta

Clinical overview. Beractant (Survanta) is a natural bovine lung surfactant given directly into a premature baby's breathing tube to prevent or treat respiratory distress syndrome (RDS). It is administered only in a hospital neonatal intensive care setting by trained staff, with close monitoring for transient changes in heart rate and oxygen levels during dosing. It has no established role outside of premature infant care.

Indication

Common therapeutic uses

  • Beractant is used for prevention (prophylaxis) of respiratory distress syndrome (RDS) in premature infants at risk of developing RDS or with evidence of pulmonary immaturity.
  • Beractant is used for treatment (rescue) of RDS confirmed by chest X-ray in premature infants who require mechanical ventilation.
  • Its use has not been evaluated in infants weighing less than 600 g or more than 1750 g at birth, and there is no controlled experience combining it with experimental RDS therapies such as high-frequency ventilation or extracorporeal membrane oxygenation.

Pregnancy

Risk assessment and monitoring considerations

  • Beractant is administered directly to premature infants after birth, not to pregnant women, so pregnancy-related dosing information does not apply.

Breastfeeding

Infant exposure considerations

  • Beractant is administered directly to premature infants after birth, not to breastfeeding mothers, so breastfeeding-related dosing information does not apply.

Geriatrics

Dosing and tolerability considerations

  • Beractant is used exclusively in premature infants and has no role in geriatric care.

Pediatrics

Use in children and adolescents

  • Beractant's safety and efficacy have been established specifically in premature infants with or at risk of RDS.
  • It should be administered only by, or under the supervision of, health professionals experienced in intubation, ventilator management, and general care of premature infants.

Dosage & Administration

Practical dosing and administration

  • Each dose of beractant is 100 mg phospholipids per kg of birth weight (4 mL/kg), determined from the manufacturer's weight-based dosing chart; the infant is not reweighed for repeat doses.
  • For prevention, give the first dose as soon as possible after an airway is established, preferably within 15 minutes of birth, in infants under 1250 g birth weight or with evidence of surfactant deficiency.
  • For rescue treatment, give the first dose as soon as possible after RDS is confirmed by X-ray and the infant requires mechanical ventilation, preferably by 8 hours of age.
  • Each dose is divided into 2 half-doses or 4 quarter-doses, instilled through a catheter into the endotracheal tube with the infant repositioned between fractional doses to ensure even lung distribution.
  • Repeat doses may be given no sooner than 6 hours after the preceding dose if the infant remains intubated and still requires at least 30% inspired oxygen; radiographic confirmation of RDS is recommended before a repeat dose in infants who received a prevention dose.
  • Up to 4 total doses may be given within the first 48 hours of life; no information is available on dosing more often than every 6 hours or beyond 48 hours of age.
  • Warm the vial before use by standing at room temperature for at least 20 minutes or holding in the hand for at least 8 minutes; artificial warming methods should never be used.
  • Suctioning the infant before dosing, at the clinician's discretion, may reduce the risk of mucous plugging; the infant should not be suctioned for 1 hour after dosing unless signs of airway obstruction appear.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Overdose with beractant has not been reported in humans.
  • Based on animal data, overdose might cause acute airway obstruction.
  • Treatment of overdose would be symptomatic and supportive.

Common side effects

Frequently reported tolerability concerns

  • Transient bradycardia (slowed heart rate) commonly occurs during the dosing procedure.
  • Transient oxygen desaturation commonly occurs during the dosing procedure.
  • Pallor may occur during dosing.
  • Vasoconstriction may occur during dosing.
  • Transient low blood pressure (hypotension) may occur during dosing.
  • Transient high blood pressure (hypertension) may occur during dosing.
  • Low carbon dioxide levels (hypocarbia) may occur during dosing.
  • High carbon dioxide levels (hypercarbia) may occur during dosing.
  • Brief pauses in breathing (apnea) may occur during dosing.
  • Rales or moist breath sounds can occur transiently after administration.
  • Reflux of beractant back up through the endotracheal tube may occur during dosing.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Endotracheal tube blockage from mucous plugs can occur, particularly if pulmonary secretions were prominent before dosing; a blocked tube should be replaced immediately if suctioning does not clear it.
  • Hyperoxia (excess blood oxygen) can develop rapidly after administration; failure to reduce ventilator support promptly can lead to lung overdistention and fatal pulmonary air leaks.
  • Pulmonary hemorrhage has been reported.
  • Increased risk of post-treatment sepsis has been observed, though it has not been associated with increased mortality.
  • Intracranial hemorrhage has been reported, with a higher rate seen in beractant-treated infants than controls in some individual studies, though pooled data across all controlled studies showed no overall difference.
  • Seizures have been reported.
  • Intestinal perforation has been reported.
  • Volvulus (twisting of the bowel) has been reported.
  • Coagulopathy (a blood clotting disorder) has been reported.
  • Renal failure has been reported.
  • Aortic thrombosis has been reported.
  • Seek immediate medical attention for signs of airway obstruction, a sudden drop in oxygen saturation, or a significant change in heart rate during or after dosing.

Use with caution

Situations requiring closer assessment

  • Administer only in a highly supervised clinical setting with immediate availability of health professionals experienced in intubation, ventilator management, and care of premature infants.
  • Monitor systemic oxygenation frequently and carefully after administration, since oxygenation and lung compliance can improve rapidly and hyperoxia can develop within minutes.
  • Monitor arterial or transcutaneous oxygen and carbon dioxide levels before, during, and after administration.
  • Suction infants with prominent pulmonary secretions before dosing to reduce the risk of endotracheal tube mucous plugging.
  • If bradycardia or oxygen desaturation occurs during dosing, stop the dosing procedure and initiate appropriate measures before resuming.
  • If reflux through the endotracheal tube occurs, stop administration and increase peak inspiratory pressure as needed until the tube clears.
  • Use has not been evaluated in infants under 600 g or over 1750 g birth weight.
  • No controlled experience exists using beractant together with experimental RDS therapies such as high-frequency ventilation or extracorporeal membrane oxygenation.

Contraindications

Situations where therapy may be inappropriate

  • There are no known contraindications to treatment with beractant.

Drug interactions

Clinically relevant combinations

  • No formal drug-drug interaction studies have been conducted with beractant.

Food interactions

Meal-related administration

  • Not applicable; beractant is given by intratracheal instillation to premature infants, not taken by mouth.

Time of administration

Practical scheduling

  • Beractant is given intratracheally in a hospital neonatal intensive care setting as soon as clinically indicated for prevention or rescue treatment of RDS, not on a schedule tied to meals or time of day.

Storage

Product handling

  • Store unopened vials refrigerated at 2°C to 8°C and protect from light.
  • Vials warmed to room temperature but not used may be returned to the refrigerator once within 24 hours of warming; beractant should never be warmed and returned to the refrigerator more than once.
  • Each single-use vial should be entered with a needle only once; discard any used vial with residual drug.

Patient take-away

Key counselling points for a quick closing summary

  • Beractant (Survanta) is a lung surfactant given directly into a premature baby's breathing tube in the neonatal intensive care unit to help prevent or treat respiratory distress syndrome.
  • The medical team monitors the baby's heart rate, oxygen levels, and breathing closely during and after each dose, since brief changes can occur during the dosing procedure itself.
  • Parents can ask their baby's care team about the number of doses planned and how their baby is responding to treatment.

References

Source material and product information

  1. Health Canada Product Monograph — Beractant

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.